Ruzic et al.’s (2022) study discovered two HDAC6 inhibitors with anti-breast cancer activity. As for AD, HDAC6, has shown elevated levels in AD with direct interaction with the tau protein (Qureshi and Chinnathambi, 2022) while Sreenivasmurthy et al.’s (2022) study shows that inhibiting HDAC6 leads to activation of chaperone-mediated autophagy and alleviation of tau pathology in AD models. Here, MAPT is linked to Alzheimer disease.